Paysign is a high-quality, fast-growing payments business with a wide moat and cheap growth-adjusted valuation, but the price is above the analyst target, insiders are heavy sellers and earnings surprises have been uneven.
Thesis pillars
- Rapid Revenue Growth→Stable
- High Quality Wide Moat→Stable
- Price Above Analyst Target↑Improving
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026, based on the 10-K filed Mar 25, 2026
Paysign, Inc. (PAYS) Stock Analysis
Temporary headwind edge
Technology · Software - Infrastructure
Wait for pullback to $13.39. Price sits above the model's entry target of $13.39; the risk/reward becomes favorable on a pullback. Key risks: Analyst target reached - limited upside remaining; Sector modifier (Technology): -0.8.
Paysign is a vertically integrated provider of prepaid card products and payment processing services for corporate, consumer, and government customers, marketed under the Paysign brand, spanning corporate incentives, pharmaceutical patient affordability, plasma donor... Read more
Wait for pullback to $13.39. Price sits above the model's entry target of $13.39; the risk/reward becomes favorable on a pullback. Key risks: Analyst target reached - limited upside remaining; Sector modifier (Technology): -0.8. Chart setup: No clear chart pattern; technical signals are mixed. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 0.24, quality 7.5/10, growth 10.0/10). Score 6.1/10, moderate confidence.
Passes 4/8 gates (no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and clean insider activity. Suitability: aggressive.
About Paysign, Inc.
About Paysign, Inc.
Paysign managed approximately 670 card programs serving 8.4 million cardholders as of December 31, 2025, spanning corporate incentive, pharmaceutical patient affordability, plasma donor compensation, and general purpose reloadable prepaid card programs. The company's Paysign Plasma Donor Compensation Prepaid Card serves approximately 48% of plasma collection centers in the United States and Puerto Rico, a niche the company entered in 2011, while its Apherion software platform serves blood and plasma collection organizations with donor management and compensation optimization tools.
Paysign earns revenue from fees generated across the prepaid card lifecycle, including cardholder fees, interchange, card program management fees, transaction claims processing fees, breakage, and settlement income, since the company does not hold a banking license and issues cards only through relationships with sponsoring bank partners. Pharmaceutical patient affordability programs pay all or a portion of a patient's out-of-pocket prescription costs on behalf of sponsoring pharmaceutical manufacturers, processed either through pharmacy transactional networks or Paysign's own internal medical-claims adjudication platform, which the company says delivers faster payments to healthcare providers than competing products. Apherion, Paysign's life science technology offering, generates revenue from licensing, hosting, and consulting fees rather than card transactions.
Show full overview
Paysign's own disclosures state the company has no major customers and is not reliant on any individual card program, a genuinely diversified base across roughly 670 programs. The more material dependency the 10-K flags is structural rather than customer-specific: because Paysign lacks its own banking license, its ability to issue open-loop cards depends entirely on relationships with card-issuing bank partners, and a portion of its revenue is tied to interchange rates set by card networks that have declined in the past following Dodd-Frank rulemaking and could decline further under future legislation.
See also: Technology · Software - Infrastructure
From Paysign, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-10-29Recent Developments — Paysign, Inc.
Latest news
- NEWS A Look at PaySign Inc (PAYS) After 4.9% Gain -- GF Value $6.76 v - GuruFocus — GuruFocus positive
- NEWS Paysign price target raised to $15 from $12 at DA Davidson - TipRanks — TipRanks positive
- NEWS Paysign price target raised to $15 from $12 at DA Davidson - tipranks.com — tipranks.com positive
- NEWS PAYS Maintained by DA Davidson -- Price Target Raised to $15.00 - GuruFocus — GuruFocus positive
- NEWS DA Davidson raises Paysign stock price target to $15 on growth outlook - Investing.com India — Investing.com India positive
Generated 2026-10-29T11:53:51Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $13.39. Price sits above the model's entry target of $13.39; the risk/reward becomes favorable on a pullback. Key risks: Analyst target reached - limited upside remaining; Sector modifier (Technology): -0.8. Chart setup: No clear chart pattern; technical signals are mixed. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 0.24, quality 7.5/10, growth 10.0/10). Analyst target $12.27 reached (−12.2%), stop $12.45 (−12.2%), A.R:R -1.0:1. Score 6.1/10, moderate confidence.
Analyst target $12.27 reached (−12.2% from $13.97); no take-profit level is published. Analyst target $12.27 reached (−12.2%), stop $12.45 (−12.2%), A.R:R -1.0:1. Stop-loss: $12.45.
Analyst target reached - limited upside remaining; Sector modifier (Technology): -0.8; Negative momentum.
Paysign, Inc. trades at a P/E of 51.7 (forward 22.7). TrendMatrix value score: 4.7/10. Verdict: Buy (Wait for Entry).
11 analysts cover PAYS with a consensus score of 4.3/5. Average price target: $14.
What does Paysign, Inc. do?Paysign is a vertically integrated provider of prepaid card products and payment processing services for corporate,...
Paysign is a vertically integrated provider of prepaid card products and payment processing services for corporate, consumer, and government customers, marketed under the Paysign brand, spanning corporate incentives, pharmaceutical patient affordability, plasma donor compensation, and general purpose reloadable cards. The company also offers Apherion, a cloud-based life science technology platform for blood and plasma collection organizations. As of December 31, 2025, Paysign managed approximately 670 card programs with 8.4 million cardholders and served approximately 48% of plasma collection